[Antiviral immunization of immunocompromised adults, literature review].
OBJECTIVE
Immunization, by preventing infections, has a major interest for the immunocompromised subjects. The aim of this article is to make a point on data concerning efficacy (in terms of immunogenicity) and safety of viral vaccines available in France and to synthesize existing guidelines for four groups of patients: solid organ and hematopoietic stem cell transplant recipients, HIV infected persons and patients treated by immunosuppressive drugs for a systemic disease.


BACKGROUND
Available data about vaccines immunogenicity and safety for immunocompromised adults are rare. However, those data indicate that, when immunization contraindications and recommendations are applied, vaccines remain well tolerated and most of the time immunogenic, even if the percentage of responders is lower compared to non immunocompromised persons. Still, the specific guidelines that have been elaborated for immunization of immunocompromised adults are imprecise and incomplete, emphasizing a lack of data about this topic.


CONCLUSIONS
Clinical studies remain necessary to precise vaccines immunogenicity and safety for immunocompromised adults. In the meantime, a harmonization of immunization practices for immunocompromised adults should be proposed, so as to help practitioners to succeed a better immunization coverage for these patients.
Duchet Niedziolka
P
P
CIC de vaccinologie Cochin-Pasteur, pôle de médecine interne, groupe hospitalier Cochin-Saint-Vincent-de-Paul, Assistance publique-Hôpitaux de Paris, université René-Descartes Paris-5, 75679 Paris cedex, France.
Launay
O
O
Salmon Ceron
D
D
Consigny
P-H
PH
Ancelle
T
T
Van der Vliet
D
D
Lortholary
O
O
Hanslik
T
T
D016915:AIDS Vaccines / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D019433:Chickenpox Vaccine / Q000009:adverse effects / Q000627:therapeutic use; D022362:Hepatitis A Vaccines / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007114:Immunization / Q000379:methods*; D016867:Immunocompromised Host / Q000276:immunology*; D012449:Safety; D014765:Viral Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D022341:Yellow Fever Vaccine / Q000009:adverse effects / Q000627:therapeutic use
D016915:AIDS Vaccines; D019433:Chickenpox Vaccine; D022362:Hepatitis A Vaccines; D014765:Viral Vaccines; D022341:Yellow Fever Vaccine